Super Generics Market Outlook: Trends, Opportunities, and Challenges

The super generics market comprises drugs that are therapeutically equivalent to patented drugs whose patent protection has expired. These drugs provide comparable efficacy and safety to patented drugs at a fraction of prices, offering significant cost savings for patients, pharmaceutical companies, and healthcare systems. Rising healthcare costs have prompted regulatory authorities worldwide to encourage the production and use of super generics. 

The super generics market is estimated to be valued at USD 84 Bn in 2024 and is expected to reach USD 200 Bn by 2031, growing at a compound annual growth rate (CAGR) of 8.3% from 2024 to 2031.

Key players operating in the super generics market are Teva Pharmaceuticals, Mylan Pharmaceuticals, Novartis AG (Sandoz), Pfizer Inc., and Dr. Reddy’s Laboratories.

The rising demand for affordable healthcare is a key driver propelling the growth of the super generics market. With branded drugs becoming exceedingly expensive, Super Generics Market have emerged as a cost-effective alternative for patients. According to the World Health Organization (WHO), more than half the world’s population cannot access essential medicines due to high prices. The pandemic-led economic distress has further amplified the demand for low-cost medicines globally.

Major drugmakers are aggressively expanding their super generics product portfolios and global footprint to leverage the substantial market potential. Teva, for example, has strengthened its portfolio of generics and super generics through acquisitions and built manufacturing facilities worldwide. Mylan focuses on developing complex generics and has a strong market presence across Europe, Australia, and emerging markets. The impending patent cliff of many blockbuster drugs will also create numerous opportunities for super generic manufacturers over the coming years.

Market Key Trends
One of the key trends driving the super generics market is the growing pipeline of products awaiting patent expiry of large pharmaceutical brands. Blockbusters worth over $200 billion in annual sales are expected to lose exclusivity between 2023 to 2027. This includes popular drugs like Humira, Revlimid, Eliquis, and Opdivo. Once patents expire, multiple super generic versions are launched by competitors at deep discounts, improving access and affordability significantly. Super generic manufacturers are making large investments in R&D and manufacturing to be ready with robust pipelines to tap into these lucrative upcoming opportunities. This, in turn, will substantially boost revenues and profitability for major players in the industry.

Porter's Analysis
Threat of new entrants: The risk of new companies entering the market is moderate as expertise and investment is required to produce generics at scale. However, opportunities exist for smaller firms to service niche therapeutic areas or territories.
Bargaining power of buyers: Purchasing groups and public drug plans have significant bargaining power to negotiate lower drug prices from generic manufacturers. This encourages price competition between generics producers.
Bargaining power of suppliers: Important raw material and API suppliers hold some power, as switching costs are incurred. However, the availability of alternative sources limits the ability of any single supplier to significantly influence prices.
Threat of new substitutes: The threat is moderate, as therapy areas with patent expiries draw new generic competitors. Brand-name drugs losing exclusivity pose a continuing threat of lower-cost substitutes.
Competitive rivalry: Intense price competition exists between multinational generic producers. Larger players acquire smaller firms to reduce rivals and gain economies of scale.

Geographical Regions
North America represents the largest super generics market currently, valued at over $35 billion. The U.S. accounts for the vast majority of sales due to its large population and drug costs. Generics have made prescription drugs more affordable for many Americans.

The Asia Pacific region excluding Japan is growing the fastest for super generics, projected to expand over 8% annually. Rising incomes are improving healthcare access in populous nations like India, China, and Indonesia. Government efforts to prioritize generics are also fueling market growth. India has emerged as a global manufacturing leader, while China is becoming an important new market. 

Get this Report in Japanese Language: スーパージェネリック市場

Get this Report in Korean Language: 슈퍼 제네릭 마켓

About Author:

Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)